Eisai Co., Ltd. (TYO:4523)
4,560.00
+118.00 (2.66%)
Feb 5, 2026, 3:30 PM JST
Eisai Revenue
Eisai had revenue of 197.36B JPY in the quarter ending September 30, 2025, with 0.70% growth. This brings the company's revenue in the last twelve months to 804.39B, up 6.79% year-over-year. In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B with 6.42% growth.
Revenue (ttm)
804.39B
Revenue Growth
+6.79%
P/S Ratio
1.56
Revenue / Employee
73.68M
Employees
10,917
Market Cap
1.25T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
| Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
| Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
| Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
| Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.46T |
| Toho Holdings | 1.53T |
| Shionogi & | 465.38B |
| Sumitomo Pharma | 453.40B |
| Towa Pharmaceutical | 266.67B |
| Sawai Group Holdings | 200.00B |
| Tsumura & Co. | 181.92B |
| Nippon Shinyaku | 160.55B |
Eisai News
- 10 days ago - FDA Accepts To Priority Review Eisai And Biogen's LEQEMBI SBLA For Early Alzheimer's Disease - Nasdaq
- 10 days ago - FDA Grants Priority Review To Eisai And Biogen's SBLA For LEQEMBI Subcutaneous Autoinjector - Nasdaq
- 10 days ago - FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - Benzinga
- 10 days ago - FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - Benzinga
- 22 days ago - LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Eisai Co Ltd (4523) - GuruFocus
- 24 days ago - Nuvation Bio (NUVB) Expands Global Reach with Eisai Collaboration - GuruFocus
- 7 weeks ago - China’s new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms? - South China Morning Post
- 2 months ago - Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript - Seeking Alpha